BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 8136318)

  • 1. The change of melanocyte cytotoxicity after systemic steroid treatment in vitiligo patients.
    Hann SK; Kim HI; Im S; Park YK; Cui J; Bystryn JC
    J Dermatol Sci; 1993 Dec; 6(3):201-5. PubMed ID: 8136318
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evidence for immunologic mechanisms in human vitiligo: patients' sera induce damage to human melanocytes in vitro by complement-mediated damage and antibody-dependent cellular cytotoxicity.
    Norris DA; Kissinger RM; Naughton GM; Bystryn JC
    J Invest Dermatol; 1988 Jun; 90(6):783-9. PubMed ID: 3373009
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hydroxychloroquine protects melanocytes from autoantibody-induced injury by reducing the binding of antigen-antibody complexes.
    Li DG; Hu WZ; Ma HJ; Liu W; Yang QQ; Zhao G
    Mol Med Rep; 2016 Aug; 14(2):1275-82. PubMed ID: 27277530
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of autoantibody to melanocytes and characterization of vitiligo antigen in vitiligo patients.
    Park YK; Kim NS; Hann SK; Im S
    J Dermatol Sci; 1996 Feb; 11(2):111-20. PubMed ID: 8869031
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Apoptosis of melanocytes in vitiligo results from antibody penetration.
    Ruiz-Argüelles A; Brito GJ; Reyes-Izquierdo P; Pérez-Romano B; Sánchez-Sosa S
    J Autoimmun; 2007 Dec; 29(4):281-6. PubMed ID: 17888626
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Further evidence for involvement of both cell mediated and humoral immunity in generalized vitiligo.
    Abdel-Naser MB; Krüger-Krasagakes S; Krasagakis K; Gollnick H; Abdel-Fattah A; Orfanos CE
    Pigment Cell Res; 1994 Feb; 7(1):1-8. PubMed ID: 8072943
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Elevated serum antimelanocyte antibody level in cerebriform intradermal nevus with vitiligo.
    Lee CH; Yu HS
    J Dermatol; 2004 Jul; 31(7):540-5. PubMed ID: 15492418
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Coexistence and relationship of antikeratinocyte and antimelanocyte antibodies in patients with non-segmental-type vitiligo.
    Yu HS; Kao CH; Yu CL
    J Invest Dermatol; 1993 Jun; 100(6):823-8. PubMed ID: 8496622
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Detection of serum autoantibodies to melanocyte and correlation between melanoma antigen recognized by T-cells and vitiligo in children].
    Chen JP; Li HP; Jin SH; Zhang JT; Li J
    Nan Fang Yi Ke Da Xue Xue Bao; 2009 Oct; 29(10):2107-8, 2111. PubMed ID: 19861278
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detection of serum anti-melanocyte antibodies and identification of related antigens in patients with vitiligo.
    Zhu MC; Liu CG; Wang DX; Zhan Z
    Genet Mol Res; 2015 Dec; 14(4):16060-73. PubMed ID: 26662399
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased sensitivity of melanocytes to oxidative stress and abnormal expression of tyrosinase-related protein in vitiligo.
    Jimbow K; Chen H; Park JS; Thomas PD
    Br J Dermatol; 2001 Jan; 144(1):55-65. PubMed ID: 11167683
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IgG anti-melanocyte antibodies purified from patients with active vitiligo induce HLA-DR and intercellular adhesion molecule-1 expression and an increase in interleukin-8 release by melanocytes.
    Li YL; Yu CL; Yu HS
    J Invest Dermatol; 2000 Dec; 115(6):969-73. PubMed ID: 11121127
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytolytic antibodies to melanocytes in vitiligo.
    Cui J; Arita Y; Bystryn JC
    J Invest Dermatol; 1993 Jun; 100(6):812-5. PubMed ID: 8496621
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current remedies for vitiligo.
    Abu Tahir M; Pramod K; Ansari SH; Ali J
    Autoimmun Rev; 2010 May; 9(7):516-20. PubMed ID: 20149899
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of PUVA therapy on melanocytes and keratinocytes in non-segmental vitiligo: histopathological, immuno-histochemical and ultrastructural study.
    Anbar TS; El-Sawy AE; Attia SK; Barakat MT; Moftah NH; El-Ammawy TS; Abdel-Rahman AT; El-Tonsy MH
    Photodermatol Photoimmunol Photomed; 2012 Feb; 28(1):17-25. PubMed ID: 22211999
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Autoimmune melanocyte destruction in vitiligo.
    van den Wijngaard R; Wankowicz-Kalinska A; Pals S; Weening J; Das P
    Lab Invest; 2001 Aug; 81(8):1061-7. PubMed ID: 11502857
    [No Abstract]   [Full Text] [Related]  

  • 17. Aspirin reduces serum anti-melanocyte antibodies and soluble interleukin-2 receptors in vitiligo patients.
    Zailaie MZ
    Saudi Med J; 2005 Jul; 26(7):1085-91. PubMed ID: 16047057
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vitiligo coexistent with nevus depigmentosus.
    Kang IK; Hann SK
    J Dermatol; 1996 Mar; 23(3):187-90. PubMed ID: 8935629
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the effect of 8-methoxypsoralen (8-MOP) plus UVA (PUVA) on human melanocytes in vitiligo vulgaris and in vitro.
    Kao CH; Yu HS
    J Invest Dermatol; 1992 May; 98(5):734-40. PubMed ID: 1569322
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Less keratinocyte-derived factors related to more keratinocyte apoptosis in depigmented than normally pigmented suction-blistered epidermis may cause passive melanocyte death in vitiligo.
    Lee AY; Kim NH; Choi WI; Youm YH
    J Invest Dermatol; 2005 May; 124(5):976-83. PubMed ID: 15854039
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.